Retatrutide, a new dual stimulator of the GLP-1 binding site and glucose-dependent released polypeptide (GIP) binding site , is showing promising data in initial clinical studies. Ongoing examination https://bouchesocial.com/story23629050/retatrutide-emerging-studies-and-projected-therapeutic-uses